Edoxaban is one of the direct oral anticoagulants, exerting an anticoagulant effect by inhibiting activated factor X.
Changes in the prothrombin time (PT), international normalized ratio (INR), and activated partial thromboplastin time (aPTT) may be observed in patients on therapeutic edoxaban doses. However, these changes tend to be small, unpredictable, and highly variable, so clinicians should not use these markers to monitor the anticoagulant effects or titrate the dose of edoxaban (Plitt A, Giugliano RP. Edoxaban: review of Pharmacology and key phase I to III clinical trials. J Cardiovasc Pharmacol Ther. 2014;19(5):409–416).
Urgent requests should be discussed with the laboratory prior to receiving the sample.
This test will be reviewed by UKAS for ISO 15189 accreditation at the next surveillance visit in October 2019
- Created on .
- Last updated on .